Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.
JSON
Treis D, Umapathy G, Fransson S, Guan J, Mendoza-García P, Siaw JT, Wessman S, Gordon Murkes L, Stenman JJE, Djos A, Elfman LHM, Johnsen JI, Hallberg B, Palmer RH, Martinsson T, Kogner P
JCO Precision Oncology 6 (6) e2100271 [2022-01-00; online 2022-01-28]
Clinical Genomics Gothenburg [Service]
Clinical Genomics Stockholm [Service]
PubMed 35085006
DOI 10.1200/PO.21.00271
Crossref 10.1200/PO.21.00271